Interferon alpha/beta receptor 1 (IFN-R-1) (IFN-alpha/beta receptor 1) (Cytokine receptor class-II member 1) (Cytokine receptor family 2 member 1) (CRF2-1) (Type I interferon receptor 1)
1_MMVVL 6_ LGATT 11_ LVLVA 16_ VAPWV 21_ LSAAA 26_ GGKNL 31_ KSPQK 36_ VEVDI 41_ IDDNF 46_ ILRWN 51_ RSDES 56_ VGNVT 61_ FSFDY 66_ QKTGM 71_ DNWIK 76_ LSGCQ 81_ NITST 86_ KCNFS 91_ SLKLN 96_ VYEEI 101_ KLRIR 106_ AEKEN 111_ TSSWY 116_ EVDSF 121_ TPFRK 126_ AQIGP 131_ PEVHL 136_ EAEDK 141_ AIVIH 146_ ISPGT 151_ KDSVM 156_ WALDG 161_ LSFTY 166_ SLVIW 171_ KNSSG 176_ VEERI 181_ ENIYS 186_ RHKIY 191_ KLSPE 196_ TTYCL 201_ KVKAA 206_ LLTSW 211_ KIGVY 216_ SPVHC 221_ IKTTV 226_ ENELP 231_ PPENI 236_ EVSVQ 241_ NQNYV 246_ LKWDY 251_ TYANM 256_ TFQVQ 261_ WLHAF 266_ LKRNP 271_ GNHLY 276_ KWKQI 281_ PDCEN 286_ VKTTQ 291_ CVFPQ 296_ NVFQK 301_ GIYLL 306_ RVQAS 311_ DGNNT 316_ SFWSE 321_ EIKFD 326_ TEIQA 331_ FLLPP 336_ VFNIR 341_ SLSDS 346_ FHIYI 351_ GAPKQ 356_ SGNTP 361_ VIQDY 366_ PLIYE 371_ IIFWE 376_ NTSNA 381_ ERKII 386_ EKKTD 391_ VTVPN 396_ LKPLT 401_ VYCVK 406_ ARAHT 411_ MDEKL 416_ NKSSV 421_ FSDAV 426_ CEKTK 431_ PGNTS 436_ KIWLI 441_ VGICI 446_ ALFAL 451_ PFVIY 456_ AAKVF 461_ LRCIN 466_ YVFFP 471_ SLKPS 476_ SSIDE 481_ YFSEQ 486_ PLKNL 491_ LLSTS 496_ EEQIE 501_ KCFII 506_ ENIST 511_ IATVE 516_ ETNQT 521_ DEDHK 526_ KYSSQ 531_ TSQDS 536_ GNYSN 541_ EDESE 546_ SKTSE 551_ELQQD
1: Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa) (PubMed:10049744, PubMed:14532120, PubMed:15337770, PubMed:2153461, PubMed:21854986, PubMed:24075985, PubMed:31270247, PubMed:33252644, PubMed:35442418, PubMed:7813427). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response (PubMed:10049744, PubMed:21854986, PubMed:7665574). Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another (PubMed:21854986, PubMed:32972995, PubMed:7665574, PubMed:7813427). The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors (PubMed:21854986, PubMed:32972995, PubMed:7526154, PubMed:7665574, PubMed:7813427). STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes (PubMed:19561067, PubMed:21854986, PubMed:32972995, PubMed:7665574, PubMed:7813427, PubMed:9121453). Can also act independently of IFNAR2: form an active IFNB1 receptor by itself and activate a signaling cascade that does not involve activation of the JAK-STAT pathway (By similarity)